SCHEMBL29424691

SCHEMBL29424691

OB(O)c1ccc(Cn2cnc3c(O)nccc32)cc1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ EGLN1 Q9GZT9 1/20 0.42
▸ HTR6 P50406 2/20 0.41
▸ AHCY P23526 4/20 0.37
▸ MET P08581 1/20 0.36
▸ NR1H4 Q96RI1 3/20 0.36
▸ CYP11B1 P15538 4/20 0.35
▸ CYP11B2 P19099 4/20 0.35
▸ HTT P42858 2/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ DCTPP1 Q9H773 1/20 0.35
▸ TNF P01375 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ LPL P06858 1/20 0.34
▸ LIPG Q9Y5X9 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22533675 1.00 EGLN1 (0.42) EGLN1HTR6AHCYMETNR1H4
SCHEMBL22533760 0.87 ADORA2A (0.54) AHCY
SCHEMBL22533673 0.86 AHCY (0.52) EGLN1HTR6AHCYLMNAMEN1
SCHEMBL29424716 0.86 AHCY (0.52) EGLN1HTR6AHCYLMNAMEN1
SCHEMBL29424873 0.86 EGLN1 (0.44) EGLN1HTR6AHCYCYP11B1CYP11B2
SCHEMBL22533661 0.86 EGLN1 (0.44) EGLN1HTR6AHCYCYP11B1CYP11B2
SCHEMBL28717002 0.82 L3MBTL1 (0.41) EGLN1HTR6AHCYCYP11B1CYP11B2
SCHEMBL22533905 0.81 EGLN1 (0.51) EGLN1HTR6AHCYNR1H4
SCHEMBL29424721 0.81 EGLN1 (0.51) EGLN1HTR6AHCYNR1H4
SCHEMBL22533835 0.81 CYP11B1 (0.41) EGLN1HTR6METNR1H4CYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4249070-A2 BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS Riboscience LLC (US) 2023-09-27 — — EP claimed
US-20220362266-A1 BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS RIBOSCIENCE LLC 2022-11-17 — — US claimed
CN-114040915-A Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors 里伯赛恩斯有限责任公司 2022-02-11 — — CN claimed
US-20250041319-A1 BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS RIBOSCIENCE LLC 2025-02-06 — — US disclosed
US-12029744-B2 Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors RIBOSCIENCE LLC (US) 2024-07-09 — — US disclosed
US-20220362266-A1 BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS RIBOSCIENCE LLC 2022-11-17 — — US disclosed
CN-114040915-A Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors 里伯赛恩斯有限责任公司 2022-02-11 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250041319-A1 BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS ENPP1, ENPP3, SMPD1 EGLN1 1932/4885HTR6 3139/4885AHCY 1785/4885
US-12029744-B2 Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors ENPP1, ENPP3, SMPD1 EGLN1 1956/4885HTR6 3108/4885AHCY 1670/4885
US-20220362266-A1 BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS ENPP1, ENPP3, SMPD1 EGLN1 1956/4885HTR6 3108/4885AHCY 1670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback